Head-to-head evidence
LNK01001 vs VC005
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1 · full Atopic Dermatitis pipeline
LNK01001
Developed by Lynk Pharmaceuticals
NCT06277245 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial in 356 patients that measured EASI-75 skin clearance and Investigator's Global Assessment response at week 16, the standard efficacy measures for atopic dermatitis. Both the 12 mg and 24 mg doses produced large, statistically significant improvements over placebo on both endpoints.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
VC005
Developed by Jiangsu Vcare Pharmatech and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT07598383 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LNK01001's landscape · VC005's landscape